Anaphylaxis is a condition some people can't avoid, but cost should not be the reason someone cannot access care.
The EpiPen's massive price surge made headlines recently, prompting maker Mylan to make a cheaper generic version.
But the FDA is about to ramp up the device's competition even further. A new blog post from the agency said it was ready to approve new EpiPen competitors as soon as they arrived.
So what's the FDA doing?
The FDA can't regulate drug prices, but has a "road map" to get EpiPen competitors on the market faster, inevitably leading to the cost of EpiPens or equivalent drugs dropping.
The agency has already approved four EpiPen-like auto-injectors, two of which are already on the market. But it insists it can't afford to have "substandard quality products" flood the market and put users' safety at risk.
WATCH | One EpiPen competitor called AdrenaClick has been on the market for years. Here's a clip of how the injector works.
Meanwhile, Mylan CEO Heather Bresch (pictured here) is set to testify before Congress on Sept. 21 regarding its price increases, CNBC reports.
Bresch is the daughter of U.S. Senator Joe Manchin, a Democrat from West Virginia.
WATCH | For more news you need, check out our 60 Second Circa.